Gastric Cancer最新文献

Impact of adjuvant therapy on outcomes of cancer of the stomach and gastroesophageal junction in the real-world. 在现实世界中，辅助治疗对胃癌和胃食管交界处癌症预后的影响。

IF 6 1区医学

Gastric Cancer Pub Date : 2025-05-16 DOI: 10.1007/s10120-025-01624-8

Steffen M Heckl, Hans-Michael Behrens, Ulrike Ebert, Dita Ulase, Florian Richter, Thomas Becker, Anne Letsch, Christoph Röcken

{"title":"Impact of adjuvant therapy on outcomes of cancer of the stomach and gastroesophageal junction in the real-world.","authors":"Steffen M Heckl, Hans-Michael Behrens, Ulrike Ebert, Dita Ulase, Florian Richter, Thomas Becker, Anne Letsch, Christoph Röcken","doi":"10.1007/s10120-025-01624-8","DOIUrl":"https://doi.org/10.1007/s10120-025-01624-8","url":null,"abstract":"Background: Since the FLOT4 gastric cancer (GC) trial, the use of adjuvant chemotherapy has been perceived as limited and its added value questioned. We wanted to objectify this perception and reassess the value of adjuvant chemotherapy in a real-world setting.Methods: In our retrospective cohort study we analyzed real-world data from 147 patients with GC or cancer of the gastroesophageal junction (AEG) who received perioperative FLOT. Data originated from clinical care at the university hospital, local hospitals and medical practices. Clinicopathologic data, survival outcomes, and targetable biomarkers were analyzed.Results: Median overall survival (OS) and tumor specific survival (TSS) were 19.4 ± 2.9 and 19.9 ± 3.1 months, respectively. 84.4% completed all cycles of neoadjuvant chemotherapy. The pathological complete response rate was 11.8%. Adjuvant chemotherapy was initiated in only 42.9%. Survival rates of patients with marked tumor regression (TRG1) were not improved by adjuvant chemotherapy. Conversely, patients with partial histopathologic response (TRG2) showed a marked trend and those with minimal histopathologic response (TRG3) showed a significantly longer survival with any number of adjuvant chemotherapy cycles (OS: 22.3 ± 2.6 months versus 8.7 ± 2.4 months, p = 0.005; TSS: 22.3 ± 4.5 months versus 8.7 ± 2.4 months, p = 0.016). Targetable biomarkers PD-L1, Claudin 18.2, HER2 and microsatellite instability were detected in 53.4%, 26.2%, 7.8%, and 3.9% of the TRG2/3 patient subset, respectively.Conclusions: In the real-world setting, adjuvant chemotherapy proved to be a critical turning point of the FLOT regimen. It should be sought-even in a reduced form-in patients with TRG2/3.","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: Spatial organization of B lymphocytes and prognosis prediction in patients with gastric cancer. 校正：胃癌患者B淋巴细胞的空间组织与预后预测。

IF 6 1区医学

Gastric Cancer Pub Date : 2025-05-16 DOI: 10.1007/s10120-025-01625-7

Ryan Yong Kiat Tay, Manavi Sachdeva, Haoran Ma, Young-Woo Kim, Myeong-Cherl Kook, Hyunki Kim, Jae-Ho Cheong, Lindsay C Hewitt, Katharina Nekolla, Günter Schmidt, Takaki Yoshikawa, Takashi Oshima, Tomio Arai, Supriya Srivastava, Ming Teh, Xuewen Ong, Su Ting Tay, Taotao Sheng, Joseph J Zhao, Patrick Tan, Heike I Grabsch, Raghav Sundar

引用次数: 0

Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancer. 循环肿瘤DNA预测her2阴性晚期胃癌患者免疫检查点阻断的临床益处

IF 6 1区医学

Gastric Cancer Pub Date : 2025-05-15 DOI: 10.1007/s10120-025-01621-x

Mei He, Congcong Ji, Zhiwei Li, Shiqing Chen, Jing Gao, Lin Shen, Cheng Zhang

{"title":"Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancer.","authors":"Mei He, Congcong Ji, Zhiwei Li, Shiqing Chen, Jing Gao, Lin Shen, Cheng Zhang","doi":"10.1007/s10120-025-01621-x","DOIUrl":"https://doi.org/10.1007/s10120-025-01621-x","url":null,"abstract":"Background: Immune checkpoint inhibitors (ICIs) are becoming more prominent in the treatment of gastric cancer (GC). However, predictive biomarkers of response to ICIs in HER2-negative patients remain incompletely understood.Methods: A total of 47 patients diagnosed with HER2-negative advanced GC who underwent ICI regimens were eligible for this study. Plasma samples with paired white blood cells prior to treatments were collected from these 47 patients. Variations of circulating tumor DNA (ctDNA) was evaluated by next-generation sequencing followed by its significance analysis.Results: A total of 658 somatic mutations involving 203 genes were identified in all ctDNA. Mutations in MEN1, MLH1, CEBPA, ATR, GNAQ, and FOXL2 genes were more frequent in responders (P < 0.05). Compared with wild-type patients, patients with CEBPA or IRS2 mutations had prolonged median progression-free survival (mPFS, P = 0.0056). Patients with co-occurring mutations in IRS2/CEBPA, IRS2/POLD1, TP53/PIK3CA, or POLD1/CEBPA had longer mPFS compared with others (P = 0.003; 0.006; 0.0166; 0.0315; respectively). Both alteration of CDKN2A alone and co-mutations with MSH6 were significantly associated with superior overall survival (OS, P = 0.0289; 0.0355; respectively). In addition, higher on-treatment ctDNA concentration or variant allele frequency (VAF) were associated with poorer response (P < 0.05). Additionally, the increased molecular alterations of POLE, FGFR2 and MDC1 seemed to indicate the acquired resistance to ICIs.Conclusions: Variation signatures captured by ctDNA as well as the kinetics of ctDNA could predict the clinical benefits of ICB in HER2-negative GC patients, which was worth further validated in large cohort.","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A phase Ib study of photoimmunotherapy with ASP-1929 in combination with nivolumab for advanced gastric cancer (GE-PIT, EPOC1901). ASP-1929联合纳武单抗治疗晚期胃癌的Ib期研究（GE-PIT, EPOC1901）。

IF 6 1区医学

Gastric Cancer Pub Date : 2025-05-15 DOI: 10.1007/s10120-025-01623-9

Tomohiro Kadota, Rika Fujii, Shohei Koyama, Daisuke Kotani, Yusuke Yoda, Miki Fukutani, Mitsuko Suzuki, Masashi Wakabayashi, Takashi Ikeno, Hironori Sunakawa, Yoshiaki Nakamura, Akihito Kawazoe, Takuma Irie, Nozomu Fuse, Akihiro Sato, Tomonori Yano, Kohei Shitara

{"title":"A phase Ib study of photoimmunotherapy with ASP-1929 in combination with nivolumab for advanced gastric cancer (GE-PIT, EPOC1901).","authors":"Tomohiro Kadota, Rika Fujii, Shohei Koyama, Daisuke Kotani, Yusuke Yoda, Miki Fukutani, Mitsuko Suzuki, Masashi Wakabayashi, Takashi Ikeno, Hironori Sunakawa, Yoshiaki Nakamura, Akihito Kawazoe, Takuma Irie, Nozomu Fuse, Akihiro Sato, Tomonori Yano, Kohei Shitara","doi":"10.1007/s10120-025-01623-9","DOIUrl":"https://doi.org/10.1007/s10120-025-01623-9","url":null,"abstract":"Background: Photoimmunotherapy with ASP-1929 (cetuximab conjugated to IRDye 700DX) and 690-nm red light has shown promising results, with a 43% objective response rate (ORR) in a phase IIa trial for recurrent head and neck squamous cell carcinoma. This study aimed to evaluate the safety and efficacy of combining photoimmunotherapy with nivolumab for advanced gastric cancer.Methods: This phase Ib open-label, single-center trial investigated the combination of photoimmunotherapy with ASP-1929 and nivolumab in patients with unresectable EGFR-positive gastric adenocarcinoma after standard chemotherapy. The dose-escalation part aimed to determine the recommended dose of laser illumination energy under endoscopy, and the expansion part assessed the safety and efficacy at the determined dose. The primary endpoint was dose-limiting toxicity (DLT), and treatment response and adverse events were evaluated.Results: Between October 2019 and April 2022, 21 patients were enrolled. All patients had previously received at least two lines of chemotherapy, with six being refractory to anti-PD-1 therapy. No DLT was observed, and the recommended dose was 100 J/cm2. Two patients achieved a partial response, and ORR was 9.5%.Conclusion: This study demonstrated that combining endoscopic photoimmunotherapy with nivolumab is safe and feasible for advanced gastric cancer.Trial registry: The trial is registered in the Japanese Registry of Clinical Trials (identifier: jRCT2080224884, https://jrct.niph.go.jp/en-latest-detail/jRCT2080224884 ).","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The RNA-binding protein YTHDF3 affects gastric cancer cell migration and response to paclitaxel by regulating EZRIN. rna结合蛋白YTHDF3通过调控EZRIN影响胃癌细胞对紫杉醇的迁移和应答。

IF 6 1区医学

Gastric Cancer Pub Date : 2025-05-14 DOI: 10.1007/s10120-025-01620-y

Patrícia Mesquita, Alexandre Coelho, Ana S Ribeiro, Luís F C Póvoas, Catarina de Oliveira, Nelson Leça, Sara Silva, Diana Ferreira, Diana Pádua, Ricardo Coelho, Carmen Jerónimo, Joana Paredes, Carlos Conde, Bruno Pereira, Raquel Almeida

{"title":"The RNA-binding protein YTHDF3 affects gastric cancer cell migration and response to paclitaxel by regulating EZRIN.","authors":"Patrícia Mesquita, Alexandre Coelho, Ana S Ribeiro, Luís F C Póvoas, Catarina de Oliveira, Nelson Leça, Sara Silva, Diana Ferreira, Diana Pádua, Ricardo Coelho, Carmen Jerónimo, Joana Paredes, Carlos Conde, Bruno Pereira, Raquel Almeida","doi":"10.1007/s10120-025-01620-y","DOIUrl":"https://doi.org/10.1007/s10120-025-01620-y","url":null,"abstract":"Background: Gastric cancer (GC) is the fourth most common cause of cancer-related mortality and the fifth most common cancer worldwide. Despite efforts, the identification of biomarkers and new therapeutic approaches for GC remains elusive. Recent studies have begun to reveal the role of N6-adenosine methylation (m6A) in the regulation of gene expression.Methods: The expression of the reader YT521-B homology domain-containing family 3 (YTHDF3) in GC was assessed in 331 patients using immunohistochemistry. GC cell lines depleted of YTHDF3 using CRISPR-Cas9 were evaluated for migration, metastasis, orientation of the mitotic spindle, and response to paclitaxel. The association between YTHDF3 and EZRIN (EZR) mRNA was shown using RNA sequencing, immunofluorescence, real-time PCR, and RNA immunoprecipitation. The single-base elongation- and ligation-based qPCR amplification (SELECT) method was used to map m6A in the EZR transcript.Results: YTHDF3 was significantly overexpressed in GC, and high levels of YTHDF3 were predictive of the response to chemotherapy. In GC cell lines, YTHDF3 was the most highly expressed reader protein. YTHDF3 depletion impaired cytoskeleton organization, cell migration and metastasis, and orientation of the mitotic spindle, leading to an increased response to paclitaxel. EZR was one of the downregulated targets in the YTHDF3 knockout cell models and was associated with the observed phenotype.Conclusion: YTHDF3 contributes to cell motility and response to paclitaxel in GC cell lines, at least in part through EZR regulation. The YTHDF3-EZR regulatory axis is a novel molecular player in GC, with clinical relevance and potential therapeutic utility.","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Paradoxical effects of adiposity and inflammation on immunotherapy efficacy in gastric cancer: novel insights from real-world data. 肥胖和炎症对胃癌免疫治疗效果的矛盾影响：来自现实世界数据的新见解。

IF 6 1区医学

Gastric Cancer Pub Date : 2025-05-12 DOI: 10.1007/s10120-025-01622-w

Li-Li Shen, Hua-Long Zheng, Zhi-Wei Zheng, Bin-Bin Xu, Zhen Xue, Jia-Lin, Qi-Yue Chen, Jian-Wei Xie, Ping Li, Chang-Ming Huang, Jian-Xian Lin, Chao-Hui Zheng

{"title":"Paradoxical effects of adiposity and inflammation on immunotherapy efficacy in gastric cancer: novel insights from real-world data.","authors":"Li-Li Shen, Hua-Long Zheng, Zhi-Wei Zheng, Bin-Bin Xu, Zhen Xue, Jia-Lin, Qi-Yue Chen, Jian-Wei Xie, Ping Li, Chang-Ming Huang, Jian-Xian Lin, Chao-Hui Zheng","doi":"10.1007/s10120-025-01622-w","DOIUrl":"https://doi.org/10.1007/s10120-025-01622-w","url":null,"abstract":"Background: Emerging studies suggest obesity may improve PD-1/PD-L1 inhibitor efficacy, correlating with prolonged survival, known as the 'obesity paradox'. However, the impact of this paradox and obesity-related chronic inflammation on immunotherapy for advanced gastric cancer (AGC) has not received sufficient research.Methods: Between January 2018 and December 2021, patients receiving neoadjuvant therapy were categorized into two groups: combined immunotherapy (ICIs, n = 173) and neoadjuvant chemotherapy (NAC, n = 126). Visceral (VATI) and subcutaneous adipose tissue index (SATI) were obtained from pre-treatment CT images. The systemic immune-inflammation index (SII) was calculated as platelet count multiplied by the neutrophil-to-lymphocyte ratio.Results: The median age of patients was 64 years (IQR 56-69), with 219 (73.2%) males and 80 (26.8%) females. In the ICIs group, the VATI-High group showed significantly higher 3-year overall survival (OS) (p = 0.010) and disease-free survival (DFS) (p = 0.029). Similar results were observed in the SATI analysis (p < 0.05). Conversely, OS (p = 0.040) and DFS (p = 0.039) were significantly lower in the SII-High group. Both VATI and SATI were independent protective factors for OS and DFS, but the effect disappeared after adjustment for SII. SII was associated with poorer OS and DFS, even after adjustment for VATI and SATI. No significant differences were observed in the analysis of the NAC group.Conclusions: Elevated adiposity indices (VATI/SATI) and low SII correlate with survival benefit in ICI-treated AGC patients, and importantly, this paradoxical survival benefit is dependent on SII status. In contrast, no such benefit is observed in chemotherapy-alone cohorts.","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143964040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reply to the letter to the editor regarding "Appetite-preserving gastrectomy (APG) for esophagogastric junction cancer: preserving the residual stomach as an endocrine organ". 回复关于“保胃口胃切除术（APG）治疗食管胃结癌：保留残胃作为内分泌器官”的编辑信。

IF 6 1区医学

Gastric Cancer Pub Date : 2025-05-08 DOI: 10.1007/s10120-025-01619-5

Naoki Hiki, Tadashi Higuchi

引用次数: 0

Early angiographic changes after hemostatic radiotherapy for gastric cancer bleeding, mentioning the mechanism and potential immediate effects of the treatment. 胃癌出血止血放疗后的早期血管造影改变，提及治疗的机制和潜在的即时效果。

IF 6 1区医学

Gastric Cancer Pub Date : 2025-05-02 DOI: 10.1007/s10120-025-01616-8

Yuki Wada, Motoko Konno, Tomoki Tozawa, Tomochika Sato, Tetsugaku Shinozaki, Satoshi Kumagai, Noriko Takagi, Koji Fukuda, Hiroyuki Shibata, Naoko Mori

{"title":"Early angiographic changes after hemostatic radiotherapy for gastric cancer bleeding, mentioning the mechanism and potential immediate effects of the treatment.","authors":"Yuki Wada, Motoko Konno, Tomoki Tozawa, Tomochika Sato, Tetsugaku Shinozaki, Satoshi Kumagai, Noriko Takagi, Koji Fukuda, Hiroyuki Shibata, Naoko Mori","doi":"10.1007/s10120-025-01616-8","DOIUrl":"https://doi.org/10.1007/s10120-025-01616-8","url":null,"abstract":"Although hemostatic radiotherapy has been reported as an effective treatment for gastric cancer bleeding, its mechanism and immediate effects remain unclear. We experienced a case of gastric cancer bleeding originating from both the whole gastric tumor and a left gastric arterial pseudoaneurysm at the tumor-associated ulcer. The patient was treated with radiotherapy for bleeding from the whole gastric tumor, followed by transcatheter arterial embolization for the left gastric arterial pseudoaneurysm. Angiography performed two hours after radiotherapy with an X-ray of 8 Gy in a single fraction revealed the disappearance of both tumor vessels and tumor stain from not only the embolized left gastric artery but also both the non-embolized right gastric artery and common trunk of the left gastric and the left hepatic arteries, which indicated these angiographic changes of the non-embolized arteries were presumed to reflect an immediate effect of hemostatic radiotherapy. Following hemostatic treatments, the patient's vital signs stabilized, and hemoglobin levels did not decrease, indicating immediate hemostasis. This case suggests a link between hemostatic mechanism and early tumor vessel changes, indicating that hemostatic radiotherapy can achieve rapid bleeding control. Therefore, hemostatic radiotherapy should be considered an emergency treatment option for gastric cancer bleeding.","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Japanese family of hereditary diffuse gastric cancer with a germline pathogenic variant of CTNN1A detected via comprehensive genome profiling. 一个日本家族的遗传性弥漫性胃癌与种系致病变异CTNN1A通过全面的基因组分析检测。

IF 6 1区医学

Gastric Cancer Pub Date : 2025-05-01 Epub Date: 2025-01-21 DOI: 10.1007/s10120-025-01583-0

Takeshi Kawakami, Hiroyuki Matsubayashi, Yoshimi Kiyozumi, Rina Harada, Eiko Ishihara, Masao Yoshida, Hiroyuki Ono, Etsuro Bando, Masakuni Serizawa, Takashi Sugino

引用次数: 0

Leptomeningeal carcinomatosis in gastric cancer: A Review. 胃癌轻脑膜癌的研究进展。

IF 6 1区医学

Gastric Cancer Pub Date : 2025-05-01 Epub Date: 2025-03-14 DOI: 10.1007/s10120-025-01597-8

Simran Arjani, Hyein Jeon, Bhawneet Chadha, Huda Yousuf, Enrico Castellucci

{"title":"Leptomeningeal carcinomatosis in gastric cancer: A Review.","authors":"Simran Arjani, Hyein Jeon, Bhawneet Chadha, Huda Yousuf, Enrico Castellucci","doi":"10.1007/s10120-025-01597-8","DOIUrl":"10.1007/s10120-025-01597-8","url":null,"abstract":"Gastric cancer is the fifth most common cancer worldwide and leptomeningeal carcinomatosis (LM) occurs in 0.06% of gastric cancers. As such, trials are difficult to power and quantitative analyses difficult to standardize. We composed a review and analysis of 47 recent cases to be used as a comprehensive resource for an oncologist faced with managing this highly morbid, rapidly fatal disease. Gold-standard of diagnosis of LM is through cerebral spinal fluid (CSF) cytology; MRI is the preferred imaging modality to identify LM. However, repeated lumbar punctures and imaging studies are often required to establish diagnosis. Negative results do not rule out LM. Treatment includes radiation and intrathecal chemotherapy, most commonly with methotrexate. Systemic treatment with chemotherapy and immunotherapy is also used. Median survival was 2 months. Intrathecal methotrexate was most commonly dosed at 10-12 mg and treatment continued till symptom resolution, serial lumbar punctures with negative cytology, decrease and stabilization of CSF carcinoembryonic antigen (CEA) levels, progression of disease, or poor functional status. The maximum survival was 12 months. The results of this review indicate that suspicion for leptomeningeal disease should be high in any patient with gastric malignancy or with symptoms consistent with malignancy. Treatment on a biweekly to bi-monthly basis and the addition of systemic therapy to intrathecal therapy should be studied in a matched prospective manner. And in the absence of this information, treatment with at least intrathecal chemotherapy and radiation therapy should be considered in those with a performance status conducive to continued treatment.","PeriodicalId":12684,"journal":{"name":"Gastric Cancer","volume":" ","pages":"311-325"},"PeriodicalIF":6.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11993494/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0